Topic: mitochondrial diseases
Mitochondria in diseased upper motor neurons of the brain go through a self-destructive process at an early stage of neurodegeneration in ALS.
Immuno-neurology developer Alector priced out a $176 million listing, while mitochondria-focused Stealth BioTherapeutics aims to raise $81 million.
Stealth BioTherapeutics filed to raise up to $86 million in its Nasdaq IPO, funding that will push its lead asset through the clinic in two indications.
Entrada Therapeutics debuted with $59 million and a plan to deliver biologic therapies intracellularly to treat rare and fatal monogenic diseases.
The takeover gives Astellas full control of a phase 1 DMD drug in return for $225 million upfront and the same again down the line.
The vote of confidence in the drug follows an early look at phase 2 data on the intracellular redox-modulating agent.
Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders
Scientists have identified an enzyme that’s crucial to repairing damaged mitochondrial DNA—a finding they believe will enhance the search for effective treatments for many diseases.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.
NeuroVive Pharmaceutical has entered into a research collaboration with Karolinska Institutet.